Naloxone spray market to reach $2428.63 billion by 2030 at 24.6% cagr, driven by increasing demand for telemedicine and rapid response to opioid overdose cases.
Read More
Melatonin supplements market to reach $4.89 billion by 2030 at 12.2% CAGR, driven by rising prevalence of sleep disorders.
Read More
Myeloproliferative disorders drugs market to reach $12.17 billion by 2030 at 4.6% cagr, driven by rise in incidence of myeloproliferative disorders and aging population.
Read More
Myelodysplastic syndrome drugs market to reach $3.84 billion by 2030 at 9.6% cagr, driven by rising demand for personalized medicine and genomics-based treatment approaches.
Read More
Melanoma therapeutics market to reach $7.49 billion by 2030 at 11.0% CAGR, driven by increasing incidence of melanoma.
Read More
Myelodysplastic syndrome (mds) drugs market to reach $5.56 billion by 2030 at 8.7% cagr, driven by increasing incidences of myeloid leukemia and rising research and development activities.
Read More
Melanoma drugs market to reach $17.07 billion by 2030 at 11.1% CAGR, driven by increase in the incidence of melanoma in males.
Read More
Myc proto oncogene protein market to reach $3.44 billion by 2030 at 12.6% cagr, driven by increasing number of clinical trials and rising prevalence of cancer globally.
Read More
Meganuclease genome editing market to reach $2.69 billion by 2030 at 16.9% CAGR, driven by increasing prevalence of genetic diseases.
Read More
Medulloblastoma drug market to reach $4.49 billion by 2030 at 8.2% CAGR, driven by rising incidence of brain tumors, increasing healthcare expenditure, and growing focus on personalized medicine.
Read More